Literature DB >> 1545348

Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat.

D B Haughey1, W J Jusko.   

Abstract

Bioavailability of low (10 mg/kg) and high (50 mg/kg) doses of methylprednisolone was determined after oral administration of the free alcohol of methylprednisolone and iv administration of methylprednisolone sodium succinate. Plasma concentrations of methylprednisolone and methylprednisone (reversible metabolite) were measured by HPLC. Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration. Solubilization of steroids with PEG:ethanol had no effect on their disposition. Apparent systemic clearance (CL) of methylprednisolone was 21 mL/min (low dose), approximately twice the liver blood flow. Dose-dependent changes in steady-state volume of distribution (Vdss) and central volume of distribution (Vdc), volumes, and apparent CL were observed. The methylprednisolone-to-methylprednisone AUC ratio decreased with dose due to saturation of methylprednisone formation clearance (CL12), but this is a minor metabolic pathway. The mean residence time (MRT) increased threefold with dose. Graphical estimates of the Michaelis-Menten capacity (Vmax) and affinity (Km) constants were in reasonable agreement with CL values for the low-dose experimental data. Low systemic availability of iv methylprednisolone sodium succinate was in part due to sequential first-pass hepatic metabolism of the methylprednisolone formed. Methylprednisolone disposition is complex in the rat due to extensive first-pass effects, nonlinear elimination, nonlinear distribution, and reversible metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545348     DOI: 10.1002/jps.2600810203

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

2.  Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Authors:  Y N Sun; D C DuBois; R R Almon; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

3.  Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2017-07-20       Impact factor: 4.030

4.  VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.

Authors:  Erica K M Reeves; Eric P Hoffman; Kanneboyina Nagaraju; Jesse M Damsker; John M McCall
Journal:  Bioorg Med Chem       Date:  2013-02-18       Impact factor: 3.641

5.  Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats.

Authors:  Anasuya Hazra; Nancy Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2007-09       Impact factor: 1.627

6.  Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

Authors:  Anasuya Hazra; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-02-07       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.